Drug Profile

Venetoclax - AbbVie/Genentech

Alternative Names: A-1195425.0; ABT 0199; ABT 199; GDC-0199; RG-7601; RO-5537382; Venclexta; VENCLYXTO; Venclyxto

Latest Information Update: 26 Apr 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Abbott Laboratories; Genentech; Walter and Eliza Hall Institute of Medical Research
Developer AbbVie; Celgene Corporation; Dana-Farber Cancer Institute; Emory University; Genentech; Janssen Research & Development; M. D. Anderson Cancer Center; Merck & Co; Nantes University Hospital; National Cancer Institute (USA); Nordic Lymphoma Group; Pharmacyclics; Roche; Syros Pharmaceuticals; University Health Network
Class Antineoplastics; Benzamides; Heterocyclic bicyclo compounds; Piperazines; Pyrans; Pyridines; Pyrroles; Small molecules; Sulfonamides
Mechanism of Action Apoptosis stimulants; Proto-oncogene protein c-bcl-2 inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Diffuse large B cell lymphoma; Multiple myeloma; Acute myeloid leukaemia; Chronic lymphocytic leukaemia
New Molecular Entity Yes

Marketed Acute myeloid leukaemia; Chronic lymphocytic leukaemia
Phase III Mantle-cell lymphoma
Phase II Breast cancer; Diffuse large B cell lymphoma; Follicular lymphoma; Marginal zone B-cell lymphoma; Multiple myeloma; Non-Hodgkin's lymphoma; T-cell prolymphocytic leukaemia; Waldenstrom's macroglobulinaemia
Phase I/II Chronic myelomonocytic leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma; Prostate cancer
No development reported B-cell lymphoma; Blastic plasmacytoid dendritic cell neoplasm; Cancer; Haematological malignancies; Myelodysplastic syndromes; Non-small cell lung cancer; Small cell lung cancer; Systemic lupus erythematosus

20 Feb 2026 AbbVie completes a phase III trial in Acute myeloid leukaemia (Combination therapy, Second-line therapy or greater) in Poland, Portugal, USA, Australia, Canada, China, Czech Republic, France, Germany, Greece, Hungary, Israel, Italy, Japan, Puerto Rico, Russia, South Korea, Spain, Taiwan, Turkey, the United Kingdom (PO) (NCT04102020)
20 Feb 2026 Launched for Acute myeloid leukaemia (Combination therapy, First-line therapy, In the elderly, In adults) in USA (PO)
20 Feb 2026 Launched for Chronic lymphocytic leukaemia (First-line therapy, Combination therapy) in USA (PO)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com